The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2020 | First-in-human trial of rapidly manufactured UltraCAR T-cells in R/R myeloid malignancies
David Sallman, MD, Moffitt Cancer Center, Tampa, FL, outlines the design of a Phase I/Ib first-in-human trial (NCT03927261) of CD33-targeted PRGN-3006 UltraCAR-T cells in relapsed/refractory (R/R) acute myeloid leukemia (AML), hypomethylating agent-failure higher-risk myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia. Current CAR T-cell therapies have long manufacturing and expansion periods, setting back treatment in a rapidly progressing disease. The UltraCAR-T platform uses a non-viral gene delivery system and a rapid manufacturing process that allows overnight production with no ex vivo expansion requirement. As well as CD33-CAR, PRGN-3006 UltraCAR T-cells express membrane bound IL-15, shown preclinically to cause a maintained stem-like memory phenotype. Two cohorts will be enrolled to receive the treatment using a dose-escalation design, with or without prior lymphodepletion. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
Disclosures
Advisory board: AbbVie, Agios, Aprea, BMS, Celyad, Gilead, Intellia, Kite, Novartis, Syndax
Speaker’s bureau: Agios, BMS, Incyte
Consultant: Magenta
Research funding: Celgene, Jazz
